SI-BONE (NASDAQ:SIBN) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

SI-BONE (NASDAQ:SIBN) announced its earnings results on Monday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.05, Zacks reports. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. SI-BONE updated its FY 2025 guidance to EPS.

SI-BONE Stock Performance

SIBN traded down $0.37 during trading on Monday, reaching $17.47. 480,003 shares of the company’s stock were exchanged, compared to its average volume of 337,823. SI-BONE has a 1 year low of $11.70 and a 1 year high of $20.60. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a market capitalization of $732.66 million, a P/E ratio of -18.99 and a beta of 1.17. The company’s fifty day simple moving average is $15.65 and its 200-day simple moving average is $14.66.

Insider Activity

In other news, insider Anthony J. Recupero sold 3,670 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the transaction, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. The trade was a 1.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Anshul Maheshwari sold 5,304 shares of SI-BONE stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the transaction, the chief financial officer now directly owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,311 shares of company stock valued at $130,356 in the last three months. 3.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SIBN. Truist Financial increased their target price on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of SI-BONE in a research note on Monday, January 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SI-BONE presently has a consensus rating of “Buy” and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.